Literature DB >> 16754795

Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.

Stefano Perlini1, Ivana Ferrero, Giuseppina Palladini, Rossana Tozzi, Chiara Gatti, Monia Vezzoli, Francesca Cesana, Maria Bianchi Janetti, Francesca Clari, Giuseppe Busca, Giuseppe Mancia, Alberto U Ferrari.   

Abstract

We observed previously that in rats with aortic banding (Bd), development of left ventricular (LV) hypertrophy is opposed by beta-blockade, whereas interventions interfering with alpha-adrenoceptor function also inhibit interstitial fibrosis. To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO). After monitoring survival for 10 weeks, the survivors were anesthetized to undergo echocardiography and intraarterial blood pressure measurement. Bd-Vh rats showed increased LV and lung weights, as well as LV dilation, depressed endocardial and midwall fractional shortening and a restrictive transmitral diastolic flow velocity pattern. Compared with Bd-Vh rats, all of the actively treated Bd rats showed less LV hypertrophy, LV dilation, and lung congestion but no less depression of midwall fractional shortening. In contrast, Sx and Dox but not Pro treatment were also associated with lesser degrees of diastolic dysfunction and, even more importantly, with a striking increase in survival (sham banded rats, 100%; Bd-Vh, 40%; Bd-Pro, 51%; Bd-Sx, 83%; and Bd-Dox, 82%). Although Pro, Sx, and Dox provide similar midterm protection from development of LV hypertrophy and dysfunction and from circulatory congestion, only Sx and Dox favorably affected mortality. These findings indicate that in the aortic banding rat model, alpha-adrenoceptors are importantly involved in the pathogenesis of cardiovascular deterioration and disease progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16754795     DOI: 10.1161/01.HYP.0000226859.42064.ea

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update.

Authors:  Alberto Milan; Mimma A Caserta; Eleonora Avenatti; Sara Abram; Franco Veglio
Journal:  Intern Emerg Med       Date:  2010-05-18       Impact factor: 3.397

2.  Cardiac pressure overload hypertrophy is differentially regulated by β-adrenergic receptor subtypes.

Authors:  Mingming Zhao; Giovanni Fajardo; Takashi Urashima; Joshua M Spin; Sara Poorfarahani; Viswanathan Rajagopalan; Diem Huynh; Andrew Connolly; Thomas Quertermous; Daniel Bernstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-24       Impact factor: 4.733

Review 3.  Left cardiac sympathetic denervation in patients with heart failure: a new indication for an old intervention?

Authors:  Gaetano M De Ferrari; Peter J Schwartz
Journal:  J Cardiovasc Transl Res       Date:  2014-01-31       Impact factor: 4.132

4.  Mitochondrial fission is required for cardiomyocyte hypertrophy mediated by a Ca2+-calcineurin signaling pathway.

Authors:  Christian Pennanen; Valentina Parra; Camila López-Crisosto; Pablo E Morales; Andrea Del Campo; Tomás Gutierrez; Pablo Rivera-Mejías; Jovan Kuzmicic; Mario Chiong; Antonio Zorzano; Beverly A Rothermel; Sergio Lavandero
Journal:  J Cell Sci       Date:  2014-04-28       Impact factor: 5.285

5.  Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart.

Authors:  Scott P Levick; David B Murray; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

6.  Effects of sympathectomy on myocardium remodeling and function.

Authors:  Maurício Rodrigues Jordão; Fernanda G Pessoa; Keila C B Fonseca; Fernando Zanoni; Vera M C Salemi; Leandro E Souza; Orlando N Ribeiro; Fábio Fernandes; Maria Claudia Irigoyen; Luiz Felipe P Moreira; Charles Mady; Felix Jose Alvarez Ramires
Journal:  Clinics (Sao Paulo)       Date:  2021-01-20       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.